Omalizumab and hypersensitivity reactions

Current Opinion in Allergy and Clinical Immunology

Volumn 13, Issue 1, 2013, Pages 19-24

  Shankar, Tara ^a   Petrov, Andrej A ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

desensitization; hypersensitivity reaction; immunotherapy; omalizumab

Indexed keywords

ALLERGEN; CORTICOSTEROID; ERYTHROPOIETIN; IMMUNOGLOBULIN E ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OMALIZUMAB; VENOM;

ALLERGIC ASTHMA; ANAPHYLAXIS; DESENSITIZATION; DRUG EFFICACY; DRUG RECEPTOR BINDING; FATIGUE; HUMAN; HYPERSENSITIVITY; IMMUNOTHERAPY; MYALGIA; NONHUMAN; PEANUT ALLERGY; PRIORITY JOURNAL; PRURITUS; REVIEW; TREATMENT OUTCOME; URTICARIA;

ANAPHYLAXIS; ANTI-ALLERGIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; OFF-LABEL USE;

EID: 84871978394     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32835bf3f5     Document Type: Review

References (53)

1. Sampson HA, Muñoz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report-Second National Institute of Allergy and Infectious Disease/Food Allergy and Ana-phylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391-397.
2. Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol 2002; 110:341-348.
3. Lieberman P, Camargo CA, Bohlke K, et al. Epidemiology of anaphylaxis: findings of the American College of Allergy, Asthma and Immunology Epidemiology of Anaphylaxis Working Group. Ann Allergy Asthma Immunol 2006; 97:596-602.
4. Simons FER, Ardusso LRF, Bilò MB, et al. 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol 2012; 12:389-399.
5. Fahy JV, Boushey HA. Targeting IgE with monoclonal antibodies: the future is now. Clin Exp Allergy 1998; 28:664-667.
6. Casale TB, Stokes Jr. Immunomodulators for allergic respiratory disorders. J Allergy Clin Immunol 2008; 121:288-296.
7. Kopp MV. Omalizumab: anti-IgE therapy in allergy. Curr Allergy Asthma Rep 2011; 11:101-106.
8. MacGlashan D, Lichtenstein LM, McKenzie-White J, et al. Upregulation of FceRI on human basophils by IgE antibody is mediated by interaction of IgE with FceRI. J Allergy Clin Immunol 1999; 104 (2 Pt 1):492-498.
9. Shields RL, Whether WR, Zioncheck K, et al. Inhibition of allergic reactions with antibodies to IgE. Int Arch Allergy Immunol 1995; 107:308-312.
10. Casale TB, Bernstein IL, Busse WW, et al. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 1997; 100:110-121.
11. MacGlashan DW, Bochner BS, Adelman DC, et al. Down-regulation of FceRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158:1438-1445.
12. Chang TW, Shiung Y-Y. Anti-IgE as a mast cell-stabilizing therapeutic agent. J Allergy Clin Immunol 2006; 117:1203-1212.
13. Warrier P, Casale TB. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2009; 102:257-258.
14. Jones JD, Marney SR, Fahrenholz JM. Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol 2008; 101:550-551.
15. Demirtürk M, Gelincik A, Colakoǧlu B, et al. Promising option in the prevention of idiopathic anaphylaxis: omalizumab. J Dermatol 2012; 39:552-554.
16. Bray S, Fajt M, Petrov A. Successful treatment of exercise induced anaphy-laxis with omalizumab. Ann Allergy Asthma Immunol 2012; 109:279-285.
17. Robyn J, Metcalfe DD. Systemic mastocytosis. Adv Immunol 2006; 89:169-243.
18. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 2010; 126:1099-1104.
19. Carter MC, Robyn JA, Bressler PB, et al. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007; 119:1550-1551.
20. Pitt TJ, Cisneros N, Kalicinsky C, Becker AB. Successful treatment of idiopathic anaphylaxis in an adolescent. J Allergy Clin Immunol 2010; 126:415-416; author reply 416.
21. Kontou-Fili K, Filis CI, Voulgari C, Panayiotidis PG. Omalizumab monotherapy for bee sting and unprovoked 'anaphylaxis' in a patient with systemic mastocytosis and undetectable specific IgE. Ann Allergy Asthma Immunol 2010; 104:537-539.
22. Bell MC, Jackson DJ. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy Asthma Immunol 2012; 108:383-384.
23. Douglass JA, Carroll K, Voskamp A, et al. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy 2010; 65:926-927.
24. Tartibi HM, Majmundar AR, Khan DA. Successful use of omalizumab for prevention of fire ant anaphylaxis. J Allergy Clin Immunol 2010; 126:664-665.
25. Matheu V, Franco A, Perez E, et al. Omalizumab for drug allergy. J Allergy Clin Immunol 2007; 120:1471-1472; author reply 1472-1473.
26. Leung DYM, Sampson HA, Yunginger JW, et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2008; 348:986-993.
27. Sampson HA, Leung DY, Burks AW, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol 2011; 127:1309.e1-1310.e1.
28. Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in healthcare workers with occupational latex allergy. J Allergy Clin Immunol 2004; 113:360-361.
29. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999; 341:468-475.
30. Des Roches A, Paradis L, Knani J, et al. Immunotherapy with a standardized dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. Allergy 1996; 51:430-433.
31. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameterthird update. J Allergy Clin Immunol 2011; 127 (1 Suppl):S1-S55.
32. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006; 117:169-175.
33. Kamin W, Kopp MV, Erdnuess F, et al. Safety of anti-IgE treatment with omalizumab in children with seasonal allergic rhinitis undergoing specific immunotherapy simultaneously. Pediatr Allergy Immunol 2010; 21 (1 Pt 2): e160-e165.
34. Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117:134-140.
35. Klunker S, Saggar LR, Seyfert-Margolis V, et al. Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: inhibition of IgE-facilitated allergen binding. J Allergy Clin Immunol 2007; 120:688-695.
36. Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy 2009; 39:271-279.
37. Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol 2010; 125:383-389.
38. Galera C, Soohun N, Zankar N, et al. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009; 19:225-229.
39. Schulze J, Rose M, Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007; 62:963-964.
40. Kontou-Fili K. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis. Allergy 2008; 63:376-378.
41. Nadeau KC, Schneider LC, Hoyte L, et al. Rapid oral desensitization in combination with omalizumab therapy in patients with cow's milk allergy. J Allergy Clin Immunol 2011; 127:1622-1624.
42. Genentech Inc. Xolair (omalizumab): full prescribing information. [Internet]. 2007. Available from https://wwww.gene.com/gene/products/ information/pdf/xolair-presc ribing.pdf.
43. Cox L, Platts-Mills TAE, Finegold I, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007; 120:1373-1377.
44. Limb SL, Starke PR, Lee CE, Chowdhury BA. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007; 120:1378-1381.
45. Cox L, Lieberman P, Wallace D, et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma & Immunology Omalizumab-Associated Anaphylaxis Joint Task Force follow-up report. J Allergy Clin Immunol 2011; 128:210-212.
46. Lin RY, Rodriguez-Baez G, Bhargave GA. Omalizumab-associated anaphylactic reactions reported between January 2007 and June 2008. Ann Allergy Asthma Immunol 2009; 103:442-445.
47. Barry PJ, O'Mahony A, Finnegan C, O'Connor TM. Delayed allergic reactions to omalizumab: are patients reporting all cases? J Allergy Clin Immunol 2008; 121:785-786; author reply 786.
48. Lanier BQ. Unanswered questions and warnings involving antiimmuno-globulin E therapy based on 2-year observation of clinical experience. Allergy Asthma Proc 2005; 26:435-439.
49. Price KS, Hamilton RG. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 2007; 28:313-319.
50. Steele RH, Limaye S, Cleland B, et al. Hypersensitivity reactions to the polysorbate contained in recombinant erythropoietin and darbepoetin. Nephrology (Carlton) 2005; 10:317-320.
51. Lieberman P, Rahmaoui A, Wong DA. The safety and interpretability of skin tests with omalizumab. Ann Allergy Asthma Immunol 2010; 105:493-495.
52. Dreyfus DH, Randolph CC. Characterization of an anaphylactoid reaction to omalizumab. Ann Allergy Asthma Immunol 2006; 96:624-627.
53. Owens G, Petrov A. Successful desensitization of three patients with hypersensitivity reactions to omalizumab. Curr Drug Saf 2011; 6:339-342.